Enochian Biosciences Inc. is on track to file an IND application for its innovative cancer platform around the early part or middle of next year. If successful, that would allow clinical trials to begin in the first half of next year.

Diffuse intrinsic pontine glioma (DIPG) is an almost universally fatal brain pediatric tumor and the only tumor indication where palliative radiotherapy is the current standard of care. Although chimeric antigen receptor (CAR) T-cell therapy may hold promise for treating DIPG, the elevated tumor heterogeneity and the prospect of antigen escape make the identification of additional targets crucial. Therefore, multiple targets need to be validated to facilitate a multipronged approach.

Researchers from Beijing Corregene Biotechnology Co. Ltd. presented preclinical data for CRTE7A2-01, a cell therapy candidate consisting of human T cells expressing T-cell receptors (TCRs) specific for HLA-A*02:01-restricted HPV16 E7 antigen.

Bivictrix Therapeutics plc has nominated a clinical candidate for its lead BVX-001 program, following promising in vivo efficacy data.

Domain Therapeutics SA has nominated DT-9045...

Medigene AG has announced its pipeline expansion into neoantigens with KRAS as the first target in its MDG-10xx program, a T-cell receptor engineered T cell (TCR-T) therapy being developed in combination with the company's PD1-41BB switch receptor technology.

Bioinvent International AB has received IND...

Mesenchymal glioblastoma, a phenotype associated with poor clinical outcomes, is characterized by the expression of CD44 and chitinase 3-like protein 1 (CHI3L1) in mesenchymal glioma stem cells (GSCs). CHI3L1 has been implicated in several oncogenic pathways driving mesenchymal differentiation. However, the role of CHI3L1 as a paracrine modulator of GSC states, as well as the transcriptional regulatory network induced by CHI3L1 in GSCs, remains unknown.